undamentalytics Newsletter
Sign in

Amneal Pharmaceuticals, Inc. income statement

In fiscal 2025, Amneal Pharmaceuticals, Inc. reported revenue of $3.02bn, up 8.0% on the year before, operating income of $394m (a 13.1% margin) and net income of $72.1m, or $0.22 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1,0181,0341,6631,6261,9932,0942,2122,3942,7943,0193,118
Cost of revenue4215079391,1471,3301,3251,4281,5731,7741,9051,892
Gross profit5975267163536287697858211,0201,1131,226
Research and development179171194188180202196164191186176
Selling, general and administrative119109228290327366400430476527572
Operating income285245−20−24991153−95204249394454
Income before tax215171−203−220−3631−248−40−55139201
Income tax52−1383−10411781911−14
Net income00−20−6046813−271−84−11772157
Diluted EPS——−$0.16−$2.74$0.61$0.07−$0.86−$0.48−$0.38$0.22$0.48
Diluted shares (average)——127m132m149m152m151m176m309m325m327m
EBITDA31428745−185152213−27271312451—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: AMRX vs RPRXAMRX vs JAZZAMRX vs ELAN

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amneal Pharmaceuticals, Inc.